[Form 4] KALA BIO, Inc. Insider Trading Activity

Rhea-AI Filing Summary

KALA BIO, Inc. reporting person Todd Bazemore, identified as a director and officer (President and Chief Executive Officer), was granted a stock option on 08/29/2025 to purchase 180,000 shares of common stock at an exercise price of $11.22 per share. The option vests over four years beginning on the vesting commencement date of 08/29/2025, with 1/48th of the shares vesting at the end of each successive one-month period until 08/29/2029, subject to continued service. The option lists an expiration/exercisable date of 08/28/2035. The Form 4 was signed by an attorney-in-fact on behalf of the reporting person on 09/02/2025.

Insights

Financial Analyst

TL;DR: A routine CEO equity grant of 180,000 options at $11.22 with four-year vesting; modest near-term governance impact.

This grant awards the CEO long-term upside tied to share performance while spreading vesting monthly over four years, which helps align executive incentives with shareholder interests and retention. The exercise price of $11.22 and a stated expiration date in 2035 indicate a multi-year time horizon for realization. For valuation or dilution impact, compare the 180,000-share option amount to the companys outstanding shares; that comparison is not provided in this filing.

Corporate Governance Expert

TL;DR: Standard time-based option grant with monthly vesting promotes retention; disclosure is clear and compliant.

The Form 4 discloses the grant date, total option quantity, exercise price, vesting schedule, and the reporting persons role as President and CEO. Monthly vesting over four years is a common structure that balances retention and performance alignment. The filing is complete for Section 16 reporting purposes and was timely signed by an attorney-in-fact.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bazemore Todd

(Last) (First) (Middle)

C/O KALA BIO, INC.

1167 MASSACHUSETTS AVENUE

(Street)

ARLINGTON MA 02476

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
KALA BIO, Inc. [ KALA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SEE REMARKS

3. Date of Earliest Transaction (Month/Day/Year)
08/29/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$11.22	08/29/2025		A		180,000		(1)	08/28/2035	Common Stock	180,000	$0	180,000	D

Explanation of Responses:

1. This option was granted on August 29, 2025 and vests over four years beginning on the vesting commencement date of August 29, 2025, with 1/48th of the shares underlying the option vesting at the end of each successive one-month period thereafter until August 29, 2029, subject to the Reporting Person's continued service.

Remarks:

President and Chief Executive Officer

	/s/ Mary Reumuth, Attorney-in-Fact	09/02/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.